Abstract ATP is a ligand of P2X family purinoceptors, and exogenous ATP administration evokes pain behaviors. To date, there is a lack of systematic studies to address relationships between endogenous ATP and neuropathic pain. In this report, we took advantage of a mouse model of resiniferatoxin (RTX)-induced neuropathic pain to address the role of endogenous ATP in neuropathic pain. After RTX administration, endogenous ATP markedly increased in dorsal root ganglia (DRGs) (p <0.01) and skin tissues (p<0.001). The excessive endogenous ATP was removed by apyrase, an ATP hydrolyzing enzyme, administration via either a lumbar puncture route (p<0.001) or an intraplantar injection (p<0.001), which led to the normalization of neuropathic pain. In addition, intraplantar treatment with apyrase caused mechanical analgesia. Linear analyses showed that the densities of P2X3(+) neurons (r=−0.72, p<0.0001) and P2X3(+) dermal nerves (r=−0.72, p< 0.0001) were inversely correlated with mechanical thresholds. Moreover, the contents of endogenous ATP in skin tissues were linearly correlated with P2X3(+) dermal nerves (r=0.80, p<0.0001) and mechanical thresholds (r=−0.80, p<0.0001). In summary, this study demonstrated that enhanced purinergic signalling due to an increase in endogenous ATP after RTX-induced nerve injury contributed to the development of neuropathic pain. The data in this report provide a new therapeutic strategy for pain control by targeting the endogenous ligand of purinergic signalling.
Introduction
Purinergic signalling plays an important role in the development of neuropathic pain [1] [2] [3] . Previous studies documented upregulation of the P2X3 purinoceptor in peripheral neuropathic pain, for example in mechanical injury-induced focal neuropathy [4] , in a chronic visceral pain model [5, 6] , and in chemotherapy-induced neuropathy [7] . The roles of P2X3 activation in neuropathic pain were confirmed by functional blockade [8] [9] [10] and by administering exogenous ATP, which evokes pain behaviors [11, 12] . ATP is a ligand of P2X3 purinoceptors, and previous reports indicated that the development of pain behaviors was associated with an increase in endogenous ATP [13, 14] . However, there is a lack of systematic investigations on endogenous ATP in different peripheral nervous tissues, i.e., in dorsal root ganglia (DRGs) and their corresponding peripheral processes of nerve terminals in the skin. These observations raised the issues: (1) whether there is the same endogenous ATP contents between DRGs and their cutaneous target tissues associated with the RTX-induced pain phenotype, and (2) whether endogenous ATP in different tissues has similar effects on modulating neuropathic pain.
After tissue injury, ATP can be released from injured tissues in a burst fashion which may contribute to the development of neuropathic pain behaviors [15] . We previously established a mouse model of resiniferatoxin (RTX) neuropathy with neuropathic pain resulting from degeneration of small-diameter nerves in the skin [16] and upregulation of P2X3 purinoceptors in DRGs and their corresponding nerve terminals [17] . The injury profiles of P2X3(+) DRG neuronal density in RTX neuropathy was linearly correlated with the degree of neuropathic pain behaviors [17] . This finding prompted us to ask two intriguing questions: in addition to P2X3 purinoceptor upregulation, whether endogenous ATP is released by the injured DRG and denervated skin tissues, and if so, does endogenous ATP modulate the development of neuropathic pain behaviors?
To address these issues, we used an RTX neuropathy model to investigate (1) variations in endogenous ATP contents in DRGs and skin tissues (2) the role of endogenous ATP in modulating purinergic signallingrelated neuropathic pain behaviors, and (3) the relation between endogenous ATP contents and the degree of pain behaviors.
Materials and methods

RTX neuropathy and apyrase treatment
RTX neuropathy was induced by following an established protocol [16, 17] . Briefly, RTX (Sigma, St. Louis, MO, USA) was dissolved in the vehicle (10 % Tween 80 and 10 % ethanol in normal saline). Animals (8-week-old adult male ICR mice, weighing 35-40 g) received a single dose of RTX (50 μg/kg) by an intraperitoneal injection (the RTX group) and other group received an equal volume of vehicle (the vehicle group) as the control. Mice were housed in plastic cages on a 12-h light/12-h dark cycle and were allowed ad libitum access to water and food. All procedures were conducted in accordance with ethical guidelines for laboratory animals [18] , and the protocol was approved by Kaohsiung Medical University, Kaohsiung, Taiwan. All experimental procedures were performed under anesthetization with 4 % chloral hydrate (at a dose of 100 g in 1 ml) except for the behavioral evaluations which were performed on awake mice. All efforts were made to minimize suffering of the animals.
To investigate the relationship between endogenous ATP and neuropathic pain behaviors, apyrase (Sigma) was administered through either a lumbar puncture route [19] or an intraplantar injection [17] to eliminate endogenous ATP. In this study, endogenous ATP refers to those of ATP generated by endogenous living tissues or cells that transported to extracellular space or the final product of the membranebound ectonucleotidase [20] , which is distinguished from the exogenous administered ATP. Thus, endogenous ATP serves as an extracellular signal molecule [21] . To specifically remove endogenous ATP of L4/L5 DRGs, a lumbar puncture was performed at the level of the intervertebral space between the L4 and L5 vertebrae where L4/L5 DRGs are located (Fig. 1) [19] . Briefly, apyrase was dissolved in 0.9 % normal saline (200 U/ml) and delivered by a lumbar puncture route (5 μl, 1 U/mouse) with a Hamilton microsyringe (Hamilton, Reno, NV, USA). For the intraplantar injection, an apyrase solution was administered to one hindpaw (10 μl, 100 U/ml), with the other hindpaw serving as a control. Apyrase was given immediately after RTX treatment and daily up to day 7 of RTX treatment (RTXd7).
Evaluations of the mechanical threshold
Mechanical thresholds of the hindpaw were assessed using an up-and-down method following an established protocol [17] . Briefly, a series of monofilaments (Somedic Sales AB, Hörby, Sweden) was applied to the plantar region of the hindpaw. If paw withdrawal occurred, a monofilament of a smaller caliber was applied. In the absence of paw withdrawal, a monofilament of a larger caliber was then used. Four additional stimuli with monofilaments of different calibers based on the preceding responses were applied. The mechanical threshold was calculated according to a published formula [22] . Fig. 1 Verification of the area of spread after lumbar puncture with a toluidine blue solution. The toluidine blue solution (5 μl) was administered through a lumbar puncture in the intervertebral space between the L4/L5 vertebrae (a, arrow). b The graph shows the area over which the toluidine blue solution spread after the lumbar puncture. An arrow indicates the lumbar puncture site. GM gluteus maximus muscle, L4L4 dorsal root ganglion (DRG), L5 L5 DRG, L4p pedicle of the L4 vertebra, L5p pedicle of the L5 vertebra Endogenous ATP measurements We measured the endogenous ATP content of L4/L5 DRGs and epidermal tissues by a luciferin-luciferase assay (ATPLite™ luminescence ATP detection assay system; PerkinElmer, Waltham, MA, USA) [23] . Briefly, L4 and L5 DRGs were carefully dissected, and a biopsy of the plantar skin of the hindpaws was carefully taken with a 2-mm biopsy punch (Acu-Punch, Acuderm, Ft. Lauderdale, FL, USA) and incubated in an ethylenediaminetetraacetic acid (EDTA) solution at 37°C for 30 min. After EDTA incubation, the epidermis was easily separated from the dermis without further damaging the cutaneous tissues. The epidermal tissues were used for ATP assay due to the thickness of epidermal sheet was similar than those of the dermal tissues, which had less measurement bias during ATP assay. To extract endogenous ATP from tissues, we developed an ATP extraction protocol with ultrasonic bath. Briefly, the endogenous ATP of L4/L5 DRGs and epidermal sheets were eluted by 50 μl sterilized normal saline in an ultrasonic bath for 10 min. After ultrasonic bath, the normal saline solution was carried to a new microcentrifuge tube for ATP luminescence assay following the manufacturer's instructions [23] . An ultrasonic bath was used to physically elute the extracellular ATP of DRGs and epidermal tissues rather than cell lysis for extracting intracellular ATP. ATP luminescence was detected for 10 s with a TopCount NXT reader (PerkinElmer), and the ATP concentration was measured according to a calibration curve of ATP standards. Protein contents of L4/L5 DRGs and epidermal sheets were assayed with a protein assay kit (BioRad Laboratories, Hercules, CA). The endogenous ATP content was expressed as the ATP concentration divided by the protein content (μM/μg).
Immunofluorescent staining of P2X3(+) DRGs and dermal nerves
For DRG immunofluorescent staining, two ganglia (L4 and L5) per mice were cryosectioned at 8 μm thick. For adequate sampling, every tenth section (80-μm intervals) was immunostained. Briefly, sections were quenched in 1 % H 2 O 2 in methanol and blocked with 0.5 % nonfat dry milk and 0.1 % Triton X-100 in 0.5 M Tris buffer (Tris). Sections were incubated with anti-P2X3 antiserum (rabbit, 1:400; Neuromics, Edina, MN, USA) overnight at 4°C. After rinsing in 0.5 M Tris, sections were incubated with a Texas red-conjugated secondary antibody for 1 h (1:100; Jackson ImmunoResearch, West Grove, PA, USA).
Dermal tissues were separated from the epidermis, and subcutaneous tissues were trimmed away. Dermal tissues were immersed in 4 % paraformaldehyde overnight and cryosectioned at 15 μm thick. Peripheral processes of L4/ L5 DRG neurons terminated at the plantar skin where the dermoepidermal plexus formed. The dermoepidermal plexus was beneath the epidermal layer, and this superficial layer of dermal sheets was the focus of a systematic investigation of P2X3 purinoceptor profiles on cutaneous nerves [24] . To demonstrate P2X3(+) dermal nerves, the well-established tyramide signal amplification (TSA) technique was conducted [17] . Briefly, sections were incubated with P2X3 antiserum (1:5,000; Neuromics) overnight at 4°C, a biotinylated-labeled secondary antibody (Vector, Burlingame, CA) for 1 h, and streptavidin-horseradish peroxidase (HRP) (1:100, PerkinElmer) for 30 min. Signals were amplified with the fluorescein tyramide reagent (1:50, PerkinElmer) for 3 min.
To localize P2X3 purinoceptors in cutaneous tissues, antiserum with anti-protein gene product 9.5 (PGP9.5), a pan-axonal marker, was used to confirm cutaneous nerve fibers by P2X3/PGP9.5 double-labeling immunofluorescent staining. Briefly, dermal sheets were incubated with anti-P2X3 antisera (1:5,000), followed by the TSA method described above. After rinsing in Tris buffer, sections were incubated with the anti-PGP9.5 antisera (rabbit, 1:800; UltraClone, Isle of Wight, UK), followed by a Texas red-conjugated secondary antibody for 1 h (1:100; Jackson ImmunoResearch). Sections of DRGs and dermal sheets were mounted using Vectashield (Vector) for further quantitation.
Quantitation of P2X3(+) DRG neurons and dermal nerves
We quantified P2X3(+) DRG neurons and dermal nerves following an established protocol [17] . Briefly, DRG sections were photographed at 200× under a fluorescence microscope (Axiophot microscope; Carl Zeiss, Heidelberg, Germany) in a systematic fashion to produce a montage of the entire DRG section, and only neurons with a clear nuclear profile were counted. The density of P2X3(+) DRG neurons was calculated by the numbers of DRG neurons divided by the area containing the neurons, which was measured (in neurons/mm 2 ) with Image J vers. 1.44d software (National Institutes of Health, Bethesda, MD).
For P2X3(+) dermal nerves, photographs were taken at 200× under an Axiophot fluorescence microscope (Carl Zeiss) from ten randomly selected areas, covering 30-40 % of the entire dermal sheet. The intensity of the background was subtracted from the immunofluorescence signals, and each pixel (intensity signal) was equivalent to 0.1445 μm 2 . The area of the P2X3(+) dermal nerve was divided by the selected area of the dermis. The dermal nerve density was expressed as μm 2 /mm 2 .
Experimental design and statistical analysis
The current study included two experimental designs: establishment of RTX neuropathy and an ATP-degradation study. For RTX neuropathy, there were two groups: an RTX group and a vehicle group. In the ATP-degradation study, there were two additional groups: an RTX+apyrase (apyrase) group and an RTX+saline (saline) group. According to our previous study, neuropathic pain is induced at RTXd7, is normalized by RTXd56, and persists to RTXd84 [17] . All data in the RTX neuropathy studies were evaluated on RTXd7 and RTXd84. The coding information was masked during the behavioral tests and quantification procedures. To investigate relationships among endogenous ATP contents, P2X3 pathology, and neuropathic pain, linear regression analyses were performed which included each group at each time point. There were 90 mice in total with 5-8 mice in each group. All results are expressed as the mean ± standard derivation of the mean, and a one-way analysis of variance (ANOVA) test was performed followed by Bonferroni's post-hoc test when p<0.05 was obtained.
Results
Verification of the lumbar puncture route with a toluidine blue solution
To verify the extent of the area affected by the lumbar puncture, a toluidine blue solution was injected (5 μl) by lumbar puncture into the intervertebral space between the L4 and L5 vertebrae (Fig. 1a) . This L4/L5 intervertebral region housed the L4/L5 DRG tissues rather than the L4/ L5 spinal cord because the spinal cord is terminated at the level of L1/L2 intervertebral space. After lumbar puncture, the toluidine blue solution was spread between L4/L5 vertebrae and among L4/L5 DRG tissues, but did not spread to the level superior to the L4/L5 vertebrae (Fig. 1b) . According to our toluidine blue study, it was clear that apyrase only affected the region between L4/L5 vertebrae where L4/L5 DRG tissues located.
Apyrase administration degraded endogenous ATP and relieved neuropathic pain
To test whether endogenous ATP influenced neuropathic pain behaviors, we assessed changes in endogenous ATP contents and mechanical thresholds after apyrase treatment (Fig. 2) . The ATP content was linearly correlated with the number of DRGs (r=0.97, p=0.026) (Fig. 2a) . On RTXd7, the endogenous ATP content of DRG tissues had markedly increased compared to that of the vehicle group (4.5±2.3 vs. 0.97±0.6 μM/μg, p<0.01). The increase in ATP contents of DRG tissues had become normalized by RTXd84 (1.3±0.7 μM/μg, p>0.05). After apyrase administration by lumbar puncture, the ATP content was significantly reduced compared to that on RTXd7 (0.7±0.6 μM/μg, p<0.001) and that of the saline group (3.8±1.7 μM/μg, p<0.05) (Fig. 2b) . Changes in ATP contents of skin tissues of the hindpaw showed a similar pattern to DRG tissues after RTX neuropathy and with the intraplantar apyrase injection (Fig. 2c) . In addition, endogenous ATP contents of cutaneous tissues were significantly higher than those of DRG tissues among the different groups and at each time point (Fig. 2b vs. c) .
Mechanical allodynia developed on RTXd7 (301. 8±47.2 vs. 668.2±54.4 mg, p<0.001) and had become normalized by RTXd84 (602.1±113.7 mg, p>0.05). The ATP content was correlated with the incidence of neuropathic pain, i.e., the incidence of mechanical allodynia was linked to increases in endogenous ATP contents. Mechanical allodynia was normalized by apyrase via a lumbar puncture (619.5±74.3 mg, p<0.001) and intraplantar administration (910.1±223.5 mg, p < 0.001) (Fig. 2d) . Intriguingly, intraplantar apyrase administration further caused mechanical analgesia compared to the vehicle group (p<0.01, Fig. 2d ).
Changes in P2X3(+) DRG neurons and dermal nerves after apyrase treatment in RTX neuropathy
To investigate the relationship between endogenous ATP contents and P2X3 purinoceptors, we examined changes in P2X3(+) DRG neurons and their cutaneous terminals after apyrase treatment in RTX neuropathy. P2X3 purinoceptors were expressed in small-sized DRG neurons in the vehicle group (Fig. 3a) . P2X3(+) neurons were markedly increased on RTXd7 (225.9±44.5 vs. 128.4±14.9 neurons/ mm 2 , p<0.001) and had recovered by RTXd84 (134.6±29.0 neurons/mm 2 , p>0.05) (Fig. 3b, c) . After apyrase treatment, profiles of P2X3(+) neurons were normalized (128.2±30.1 neurons/mm 2 , p<0.001) (Fig. 3d) . P2X3(+) dermal nerves showed similar profiles to P2X3(+) DRG neurons (Fig. 4) . P2X3(+) dermal nerves showed punctate profiles in the vehicle group. These punctate profiles markedly increased and had formed a reticulated pattern by RTXd7 (Fig. 4a vs. b) , and those patterns had become normalized by RTXd84 (Fig. 4c) and after intraplantar apyrase administration (Fig. 4d) . Quantitatively, changes in patterns of P2X3(+) dermal nerves paralleled those of P2X3(+) neurons in each group (Figs. 3f and 4f) . Double-labeling of P2X3/ PGP9.5 showed that P2X3 purinoceptors were highly colocalized with PGP9.5(+) dermal nerves, indicating that P2X3 purinoceptors were expressed by cutaneous nerves (Fig. 5) .
Correlations of endogenous ATP contents, P2X3 pathology, and neuropathic pain in RTX neuropathy
Linear regression analyses were performed to investigate correlations of P2X3 pathology with neuropathic pain behaviors: densities of P2X3(+) neurons (r=−0.72, p<0.0001) and P2X3 (+) dermal nerves (r=−0.72, p<0.0001) were inversely correlated with mechanical allodynia (Fig. 6a, b) . Moreover, endogenous ATP contents in the skin were linearity correlated to mechanical allodynia (r=−0.80, p<0.0001; Fig. 6c ) and densities of P2X3(+) dermal nerves (r=0.80, p<0.0001) (Fig. 6d) . In summary, the above findings imply that endogenous ATP of the skin is an effector for P2X3 upregulation and mediates the incidence of neuropathic pain.
Discussion
The main findings of the current study demonstrated that (1) there are different endogenous ATP contents in DRGs and skin tissues, (2) endogenous ATP is an effector which modulates upregulation of P2X3 neurons and their peripheral terminals, corresponding to neuropathic pain in RTX neuropathy, and (3) apyrase Fig. 2 Changes in endogenous ATP contents and mechanical thresholds by apyrase treatment in resiniferatoxin (RTX) neuropathy. Endogenous ATP contents were determined by a luciferinluciferase assay, and mechanical thresholds were evaluated with von Frey monofilaments as described in "Materials and methods" section. Apyrase was administered either by a lumbar puncture (5 μl; 200 U/ml) or an intraplantar injection (10 μl; 100 U/ml) immediately after RTX treatment daily until RTX treatment day 7 (RTXd7). Endogenous ATP contents of b dorsal root ganglion (DRG) tissues and c epidermal (skin) tissues were assayed for each group and time point. a In the luciferinluciferase assay, ATP luminescence was linearly correlated with the number of DRGs. b Changes in endogenous ATP of DRG tissues in the vehicle, RTXd7, RTXd84, apyrase, and saline groups. c Changes in endogenous ATP of skin tissues in the vehicle, RTXd7, RTXd84, apyrase, and saline groups. d Changes in mechanical thresholds in RTX neuropathy and after apyrase treatment either by a lumbar puncture (Lumbar) or an intraplantar injection (Plantar) in different groups: vehicle (blank bar), RTX (filled bar), apyrase (gray bar), and saline (slashed bar) groups. *p <0.05, **p < 0.01, ***p < 0.001 Fig. 3 Changes in P2X3(+) neurons after apyrase treatment in resiniferatoxin (RTX) neuropathy. Apyrase (5 μl; 200 U/ml) was administered by a lumbar puncture immediately after RTX treatment daily until RTX treatment day 7 (RTXd7). Immunofluorescent staining of P2X3 (+) neurons was performed with P2X3 purinoceptor antisera on dorsal root ganglion (DRG) sections of the a vehicle, b RTXd7, c RTXd84, d apyrase, and e saline groups. P2X3 purinoceptors were upregulated at RTXd7 (b) compared to the vehicle group (a) and had become normalized by RTXd84 (c). d, e After apyrase treatment, P2X3(+) neurons recovered to the baseline level of the vehicle group. These phenomena were not observed in the saline group (e). f Quantified densities of P2X3(+) neurons according to panels a-e. Vehicle group: blank bar; RTX group: filled bar; Apyrase group: gray bar; Saline group: slashed bar. Bar, 50 μm; *p<0.05, **p<0.01, ***p<0.001 Fig. 4 Changes in P2X3(+) dermal nerves after apyrase treatment in resiniferatoxin (RTX) neuropathy. Apyrase (10 μl; 100 U/ml) was administered by an intraplantar injection immediately after RTX treatment daily until RTX treatment day 7 (RTXd7). Immunofluorescent staining of P2X3(+) dermal nerves was performed with P2X3 purinoceptor antisera on dermal tissues of the a vehicle, b RTXd7, c RTXd84, d apyrase, and e saline groups. Dashed squares refer to the area of insets in panels a-e. Insets in a-e represent high magnification (×400) of P2X3(+) dermal nerves. a-c P2X3(+) dermal nerves showed a punctate pattern in the vehicle group (a). The punctate profiles of P2X3 were dense and formed a reticulate pattern on RTXd7 (b), which had become normalized by RTXd84 (c). With intraplantar apyrase treatment, patterns of P2X3(+) dermal nerves were normalized (d), but not in the saline group (e). f Quantified densities of P2X3(+) dermal nerves according to a-e. Vehicle group: blank bar; RTX group: filled bar; Apyrase group: gray bar; Saline group: slashed bar. Bar, 100 μm; 25 μm in insets; *p<0.05, **p<0.01, ***p<0.001 treatment removed the endogenous ATP, which sequentially normalized peripheral P2X3 sensitization and neuropathic pain. This study provides direct evidence of interactions of peripheral P2X3 purinoceptors and their ligand, ATP, which modulated the incidence of neuropathic pain.
Manifestations of neuropathic pain due to enhanced purinergic signalling in RTX neuropathy This study demonstrated enhanced purinergic signalling after RTX neuropathy at the levels of both the ligand and receptor, by increased ATP content and upregulation of the P2X3 purinoceptor, which contributed to neuropathic pain. Previous studies only documented upregulation of the P2X3 purinoceptor in DRG neurons in different neuropathic pain models [4, 5, 7] , and peripheral P2X3 sensitization contributed to neuropathic pain, suggesting the pathology of P2X3 purinoceptors in peripheral tissues linked to neuropathic pain [17] .
In the current study, endogenous ATP in both DRGs and cutaneous tissues acted as a ligand in modulating peripheral P2X3 sensitization and neuropathic pain. This was verified by linear regression analyses: variations in endogenous ATP were linearly correlated with P2X3 expression and the degree of neuropathic pain. The above observations were further confirmed by apyrase treatment which degraded ATP-mediated neuropathic pain behaviors also involve G protein-coupled P2Y2 purinoceptors [25, 26] which are widely expressed by DRG neurons [27] . However, P2Y2-mediated neuropathic pain behaviors required co-activation with TRPV1 receptor [27] [28] [29] . Taken together, this implies that the P2Y2 purinoceptor might have minor roles in RTXinduced neuropathic pain due to high coexpression with the TRPV1 receptor [27, 29] which was depleted by RTX [17] . In the current study, apyrase removed endogenous ATP and relieved neuropathic pain behaviors. The mechanisms through which apyrase normalizes neuropathic pain remain unclear. One possible mechanism is P2Y1 purinoceptor being activated by ADP, a product by ATP hydrolysis after apyrase, and consequentially relieving neuropathic pain [30] . These hypotheses require further exploration.
Significance of different endogenous ATP contents in peripheral tissues and clinical implications
Previous studies addressed the effect of P2X3 on neuropathic pain with pharmacological interventions, for example inactivation of P2X3 by either P2X3 antagonism [8, 14] or functional silencing [8] . However, the upstream effector for P2X3 upregulation and neuropathic pain development in those studies was not elucidated [14] . This is the first report demonstrating that RTX induced increases in endogenous ATP in DRGs and cutaneous tissues which modulated peripheral P2X3 upregulation and corresponded to the incidence of neuropathic pain.
ATP acts as neurotransmitter and is involved in nociceptive transmission [1] [2] [3] 31] . In this report, we documented the roles of endogenous ATP in neuropathic pain. Variations in endogenous ATP contents in DRGs and the skin imply that the effects of ATP acted on both neuronal soma and their peripheral terminals. Intriguingly, this report further demonstrated that the ATP contents in skin tissues were higher than those in DRG tissues. Intraplantar administration of apyrase lowered the ATP content and mechanical analgesia compared to those in vehicle mice, suggesting that endogenous ATP of skin tissues contributed more to the effect than did ATP in DRG tissues. What is the possible mechanism of increasing endogenous ATP? Extracellular ATP is in a dynamic balance due to the equal rate of ectonucleotidase activity [20] , and there are two possibilities: bursts of ATP releases from injured peripheral nerves [13, 32] and downregulation of ectonucleotidase after RTX treatment. Our previous study demonstrated that RTX induced cutaneous nerve degeneration [16] , and P2X3 purinoceptors were upregulated and preferentially expressed in injured DRG neurons which were labeled by activating transcription factor-3 (ATF3) [17] . Taken together, these observations suggested that RTX-induced neuropathic pain was attributed to increases in endogenous ATP which was released from injured DRGs and cutaneous tissues [33] and subsequently evoked pain behaviors. However, the metabolic imbalance of ectonucleotidase is an issue which needs to be explored in further studies. For example, the metabolism of ATP in the skin may regulate by the epidermal Langerhans cells which had the ectonucleotidase activity [34] . Blockage of nociceptive-related receptors is one of the clinical guidelines for neuropathic pain treatment [35, 36] . In this current report, the double-labeling study with P2X3/ PGP9.5 demonstrated that P2X3 purinoceptors were expressed in cutaneous nerves. In summary, this current finding provides a new direction of a therapeutic strategy for pain control at cutaneous nerve terminals, i.e., reducing the effector of nociceptive-related receptors by degrading excessive endogenous ATP and decreasing nociceptiverelated purinoceptor sensitization.
